It is a passive ETF that tracks an index of large, actively traded US-listed biotech companies with big market capitalizations. It offers exposure to new drug development and the growth of the biotech industry.

It suits investors who want to concentrate on large-cap biotech and are willing to accept drug development outcomes and sector volatility.

It is an ETF managed by VanEck using a passive (index-tracking) approach.

It tracks an index of large, actively traded US-listed biotech companies with big market capitalizations. Unlike products centered on small-cap biotech, it concentrates on large, high-quality biotech companies, giving it a high weighting in its top holdings and exposure to new drug development and biotech industry growth.

• Focus on large-cap biotech
• Composition with high weighting in top holdings

Assets under management (AUM) stand at $522.7M, and the total expense ratio is 0.35% per year.

The main point of comparison is its large-cap biotech focus versus small-cap biotech ETFs and broad healthcare ETFs.

Biotech is heavily influenced by clinical trial results, mergers and acquisitions, the interest rate environment, and regulation. It tends to be strong when clinical successes and M&A expectations stand out, and weak when clinical failures or concerns over drug price regulation grow. Because it centers on large caps, its volatility is somewhat lower than that of small-cap biotech.

Fund flows in biotech split depending on new drug momentum, M&A expectations, and the interest rate environment, and when interest in new drugs and biotech innovation rises, money sometimes moves into related products. It is also worth noting that performance can vary widely depending on clinical results and the regulatory environment.

Exposure to large-cap biotech is its strength, while top-holding concentration, clinical and regulatory risk, and sector volatility are considerations.

For broader biotech exposure, direct substitutes include IBB, and for an equal-weighted approach that also holds small-cap biotech, products such as XBI are also worth comparing. If you want a different biotech index, products such as FBT can also be considered. The three products shown in the table, IDNA, MEDI, and GDOC, follow genomics and immunology, healthcare, and future healthcare strategies respectively, and differ in large-cap biotech focus and composition. This ETF is differentiated by its narrower exposure to large-cap biotech.

Here are the points to check before investing in BBH. Large-cap biotech exposure is attractive, but top-holding concentration, clinical and regulatory risk, and sector volatility need to be confirmed in advance. It is also a good idea to compare it with broader biotech and healthcare products.

Clinical failures among the top large-cap biotech names, drug price regulation, and sector volatility are the main variables for short-term performance, and the high weighting in top holdings makes the fund sensitive to weakness in individual stocks. Given the nature of biotech, large swings can occur depending on news and momentum.

It is a suitable candidate for investors who want to concentrate on large-cap biotech. If you want broader biotech or small-cap exposure, compare products such as IBB and XBI, and if you want a large-cap biotech focus, it is advisable to compare this product alongside them before choosing.